Brooke E Hoots1, Teresa Finlayson1, Lina Nerlander2, Gabriela Paz-Bailey1. 1. Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia Department of Public Health Sciences, Karolinksa Institute, Stockholm, Sweden.
Abstract
BACKGROUND: Pre-exposure prophylaxis (PrEP) is an effective prevention tool for people at substantial risk of acquiring human immunodeficiency virus (HIV). To monitor the current state of PrEP use among men who have sex with men (MSM), we report on willingness to use PrEP and PrEP utilization. To assess whether the MSM subpopulations at highest risk for infection have indications for PrEP according to the 2014 clinical guidelines, we estimated indications for PrEP for MSM by demographics. METHODS: We analyzed data from the 2014 cycle of the National HIV Behavioral Surveillance (NHBS) system among MSM who tested HIV negative in NHBS and were currently sexually active. Adjusted prevalence ratios and 95% confidence intervals were estimated from log-linked Poisson regression with generalized estimating equations to explore differences in willingness to take PrEP, PrEP use, and indications for PrEP. RESULTS: Whereas over half of MSM said they were willing to take PrEP, only about 4% reported using PrEP. There was no difference in willingness to take PrEP between black and white MSM. PrEP use was higher among white compared with black MSM and among those with greater education and income levels. Young, black MSM were less likely to have indications for PrEP compared with young MSM of other races/ethnicities. CONCLUSIONS: Young, black MSM, despite being at high risk of HIV acquisition, may not have indications for PrEP under the current guidelines. Clinicians may need to consider other factors besides risk behaviors such as HIV incidence and prevalence in subgroups of their communities when considering prescribing PrEP. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Pre-exposure prophylaxis (PrEP) is an effective prevention tool for people at substantial risk of acquiring human immunodeficiency virus (HIV). To monitor the current state of PrEP use among men who have sex with men (MSM), we report on willingness to use PrEP and PrEP utilization. To assess whether the MSM subpopulations at highest risk for infection have indications for PrEP according to the 2014 clinical guidelines, we estimated indications for PrEP for MSM by demographics. METHODS: We analyzed data from the 2014 cycle of the National HIV Behavioral Surveillance (NHBS) system among MSM who tested HIV negative in NHBS and were currently sexually active. Adjusted prevalence ratios and 95% confidence intervals were estimated from log-linked Poisson regression with generalized estimating equations to explore differences in willingness to take PrEP, PrEP use, and indications for PrEP. RESULTS: Whereas over half of MSM said they were willing to take PrEP, only about 4% reported using PrEP. There was no difference in willingness to take PrEP between black and white MSM. PrEP use was higher among white compared with black MSM and among those with greater education and income levels. Young, black MSM were less likely to have indications for PrEP compared with young MSM of other races/ethnicities. CONCLUSIONS: Young, black MSM, despite being at high risk of HIV acquisition, may not have indications for PrEP under the current guidelines. Clinicians may need to consider other factors besides risk behaviors such as HIV incidence and prevalence in subgroups of their communities when considering prescribing PrEP. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
HIV; MSM; PrEP; United States; pre-exposure prophylaxis
Authors: Colleen F Kelley; Erin Kahle; Aaron Siegler; Travis Sanchez; Carlos Del Rio; Patrick S Sullivan; Eli S Rosenberg Journal: Clin Infect Dis Date: 2015-08-13 Impact factor: 9.079
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Gregorio A Millett; John L Peterson; Stephen A Flores; Trevor A Hart; William L Jeffries; Patrick A Wilson; Sean B Rourke; Charles M Heilig; Jonathan Elford; Kevin A Fenton; Robert S Remis Journal: Lancet Date: 2012-07-20 Impact factor: 79.321
Authors: Duncan A MacKellar; Kathleen M Gallagher; Teresa Finlayson; Travis Sanchez; Amy Lansky; Patrick S Sullivan Journal: Public Health Rep Date: 2007 Impact factor: 2.792
Authors: Dawn K Smith; Michelle Van Handel; Richard J Wolitski; Jo Ellen Stryker; H Irene Hall; Joseph Prejean; Linda J Koenig; Linda A Valleroy Journal: MMWR Morb Mortal Wkly Rep Date: 2015-11-27 Impact factor: 17.586
Authors: Patrick S Sullivan; Eli S Rosenberg; Travis H Sanchez; Colleen F Kelley; Nicole Luisi; Hannah L Cooper; Ralph J Diclemente; Gina M Wingood; Paula M Frew; Laura F Salazar; Carlos Del Rio; Mark J Mulligan; John L Peterson Journal: Ann Epidemiol Date: 2015-03-24 Impact factor: 3.797
Authors: Charlotte-Paige Rolle; Eli S Rosenberg; Nicole Luisi; Jeremy Grey; Travis Sanchez; Carlos Del Rio; John L Peterson; Paula M Frew; Patrick S Sullivan; Colleen F Kelley Journal: Int J STD AIDS Date: 2016-10-20 Impact factor: 1.359
Authors: Aaron J Siegler; Anna Bratcher; Kevin M Weiss; Farah Mouhanna; Lauren Ahlschlager; Patrick S Sullivan Journal: Ann Epidemiol Date: 2018-05-26 Impact factor: 3.797
Authors: Charlotte-Paige Rolle; Eli S Rosenberg; Aaron J Siegler; Travis H Sanchez; Nicole Luisi; Kevin Weiss; Scott Cutro; Carlos Del Rio; Patrick S Sullivan; Colleen F Kelley Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Matthew Garnett; Yael Hirsch-Moverman; Julie Franks; Eleanor Hayes-Larson; Wafaa M El-Sadr; Sharon Mannheimer Journal: AIDS Care Date: 2017-08-09
Authors: Deven T Hamilton; Steven M Goodreau; Samuel M Jenness; Patrick S Sullivan; Li Yan Wang; Richard L Dunville; Lisa C Barrios; Eli S Rosenberg Journal: Am J Public Health Date: 2018-11 Impact factor: 9.308
Authors: Steven A John; H Jonathon Rendina; Tyrel J Starks; Christian Grov; Jeffrey T Parsons Journal: AIDS Patient Care STDS Date: 2019-01-17 Impact factor: 5.078
Authors: David A Katz; Julia C Dombrowski; Michael Barry; Dawn Spellman; Teal R Bell; Matthew R Golden Journal: J Acquir Immune Defic Syndr Date: 2019-04-15 Impact factor: 3.731
Authors: Alyson L Singleton; Brandon D L Marshall; Xiao Zang; Amy S Nunn; William C Goedel Journal: AIDS Patient Care STDS Date: 2020-11-19 Impact factor: 5.078